Biotech Values

[mcbio]

I’m digesting the various HCV PRs from EASL and will post about them soon—probably over the weekend. If the meantime, anyone here should feel free to chime in!

Not sure if you've had a chance to digest everything yet but curious about how you think the burgeoning data from BMY and VRUS in particular on their respective NS5A and nukes reflects on the market opportunity for ACHN with its ACH-1625 PI. Have the data from the NS5A and nukes dampened the opportunity for a 2nd gen HCV PI or do you still think there will be an opportunity here down the road to co-formulate 1625 with an NS5A and/or nuke? I'm still in the latter camp because I'm not yet convinced that an NS5A and/or nuke will be enough to remove interferon and possibly ribavirin from the equation. (It may still take a third class, such as a PI.) Also, it's a large market and there will presumably be room for multiple different cocktails, at least one of which could be comprised of a PI. Notwithstanding, I could see the market keeping ACHN down for a while given the burgeoning data from BMY and VRUS and I'll still look towards that end of the year 3 month data on 1625 as a possible buying opportunity in ACHN.